Characteristics of binding of insulin-like growth factor (IGF)-I and IGF-II analogues to the type 1 IGF receptor determined by BIAcore analysis: Correlation of binding affinity with ability to prevent apoptosis

European Journal of Biochemistry

Volumn 269, Issue 3, 2002, Pages 961-968

  Forbes, Briony E ^a   Hartfield, Perry J ^b   McNeil, Kerrie A ^a   Surinya, Kathy H ^a,e   Milner, Steven J ^c   Cosgrove, Leah J ^d   Wallace, John C ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c GroPep Ltd   (Australia)

^d CSIRO   (Australia)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Apoptosis; BIAcore analysis; Insulin like growth factor (IGF); Type 1 IGF receptor

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; DNA FRAGMENT; RECOMBINANT RECEPTOR; SOMATOMEDIN B; SOMATOMEDIN B DERIVATIVE; SOMATOMEDIN C DERIVATIVE; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL CELL; APOPTOSIS; ARTICLE; BINDING AFFINITY; BIOTECHNOLOGY; CELL ASSAY; CELL PROTECTION; CELL STRAIN; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DETERMINATION; MOLECULAR WEIGHT; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; RECEPTOR BINDING; STAINING; TISSUE;

ANIMALS; APOPTOSIS; BIOSENSING TECHNIQUES; CRICETINAE; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; PC12 CELLS; RATS; RECEPTOR, IGF TYPE 1; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 0036186637     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0014-2956.2001.02735.x     Document Type: Article

References (32)

1. The role of the IGF-I receptor in apoptosis
2. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
3. Structure and function of the type 1 insulin-like growth factor receptor
4. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity
5. Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor
6. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis
7. The IGF axis and programmed cell death
8. Solution structure of human insulin-like growth factor 1: A nuclear magnetic resonance and restrained molecular dynamics study
9. Solution structure of human insulin-like growth factor. II. Relationship to receptor and binding protein interactions
10. Three-dimensional solution structure of a disulfide bond isomer of the human insulin-like growth factor-I
11. Type-2 IGF receptor: A multi-ligand binding protein
12. Insulin-like growth factor (IGF)-binding proteins: Interactions with IGFs and intrinsic bioactivities
13. Mutants of human insulin-like growth factor I with reduced affinity for the type 1 insulin-like growth factor receptor
14. The roles of tyrosines 24, 31, and 60 in the high affinity binding of insulin-like growth factor-I to the type 1 insulin-like growth factor receptor
15. Structural analogs of human insulin-like growth factor (IGF) I with altered affinity for type 2 IGF receptors
16. Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 insulin-like growth factor receptor
17. Production and functional analysis of a soluble high affinity insulin-like growth factor type 1 receptor
18. Prevention of apoptosis by insulin-like growth factor (IGF)-I and IGF-II is differentially attenuated by IGF-binding proteins in PC12 cells
19. Multiple agents rescue PC12 cells from serum-free cell death by translation-and transcription-independent mechanisms
20. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways
21. A novel hydrogel matrix on gold surfaces in surface plasmon resonance sensors for fast and efficient covalent immobilization of ligands
22. Characterization of ligand binding of a soluble human insulin-like growth factor I receptor variant suggests a ligand-induced conformational change
23. Ceramide induces apoptosis in PC12 cells
24. Production and characterization of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu3, following their expression in Escherichia coli as fusion proteins
25. [Leu27] insulin-like growth factor II is highly selective for the type-II IGF receptor in binding, cross-linking and thymidine incorporation experiments
26. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency
27. Insulin-like growth factor (IGF)-I binding to IGF-binding proteins and IGF receptors is modified by deletion of the N-terminal hexapeptide or substitution of arginine for glutamate-6 in IGF-II
28. Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1
29. Insulin and insulin-like growth factor-1 binding specificity is determined by distinct regions of their cognate receptors
30. Rat PC12 pheochromocytoma cells synthesize insulin-like growth factor-binding protein-6
31. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use
32. Insulin and analogue e3ects on protein degradation in di3erent cell types. Dissociation between binding and activity